Waltz Comments on Consolidation of Four CMS Anti-Fraud Programs Into One
November 8, 2018
Bloomberg Law
Partner Judith Waltz was quoted in a Bloomberg Law article, “Medicare Herds Four Anti-Fraud Programs Under One Roof,” about a move by the Centers for Medicare & Medicaid Services to create one mega anti-fraud program out of four component programs.
Waltz said the new program will facilitate data sharing by removing some of the silos between Medicare and Medicaid. Many health-care providers and suppliers participate in both programs, she noted, and fraud, waste and abuse are likely to cross back and forth between the two. The Medicaid program also gets a lot of federal funding, she said, so the CMS has a vested interest in rooting fraud out of that program.
Waltz said the new program will facilitate data sharing by removing some of the silos between Medicare and Medicaid. Many health-care providers and suppliers participate in both programs, she noted, and fraud, waste and abuse are likely to cross back and forth between the two. The Medicaid program also gets a lot of federal funding, she said, so the CMS has a vested interest in rooting fraud out of that program.
People
Related News
June 10, 2025
In the News
Lynn Gandhi Sheds Light on Supreme Court Tax Ruling
Foley partner Lynn Gandhi commented in the Bloomberg Tax article "High Court’s Catholic Charities Case to Go Beyond Unemployment," sharing insight on the implications of the recent Supreme Court ruling in a tax case.
June 10, 2025
In the News
James McFall Joins Iconic Athletes and Leaders in Launch of Stanford Football Alumni United
Foley & Lardner LLP is proud to announce that partner James Carlos McFall is a founding member of Stanford Football Alumni United (SFAU), a newly formed coalition of former players and leaders committed to supporting Stanford Football’s continued growth and national competitiveness.
June 6, 2025
In the News
David Rosen Comments on FDA, Compounder Conflict Over Drug Shortages
Foley & Lardner LLP partner David Rosen highlighted the U.S. Food and Drug Administration's drug shortage list in the BioSpace article, "Post-Chevron Legal Battles: Three Key Cases to Watch."